Chest pain with discordant troponin and ECG after recent GI bleed

This is non-ST-elevation ACS, most consistent with NSTEMI, because there is a rise and fall pattern of high-sensitivity troponin above the 99th percentile with a clinical ischemic presentation and ischemic ECG changes (horizontal ST depression and T-wave inversion in V4-V6).

Key reasoning points:

• ST depression with T-wave inversion is not a STEMI equivalent here; there is no ST elevation in contiguous leads, no posterior pattern, and no aVR ST elevation with diffuse depression suggesting left main disease.
• Troponin alone is not diagnostic - it can be elevated in demand ischemia, renal dysfunction, and sepsis. Here the serial rise plus typical symptoms plus ischemic ECG changes make type 1 MI the leading diagnosis.
• Type 2 MI must still be considered: anemia (Hb 10.2) and possible ongoing blood loss could contribute to supply-demand mismatch. However, the focal ischemic ECG changes and classic symptom quality favor an acute plaque event, and both mechanisms may coexist.
• Risk stratification: GRACE score components (age, HR, BP, creatinine, ST deviation, troponin rise) place him at intermediate-to-high risk, which informs timing of angiography.

Antiplatelet therapy

• Give aspirin 300 mg loading dose (chewed or crushed) unless there is active bleeding. A bleed 3 weeks ago that has been endoscopically treated and is currently quiescent is not an absolute contraindication; the thrombotic risk of untreated NSTEMI generally outweighs rebleeding risk.
• Add a P2Y12 inhibitor (e.g., clopidogrel) but consider deferring the second agent until the angiogram defines need for PCI, especially if a prolonged dual antiplatelet course would be required. If PCI is planned, load per protocol.
• Avoid prasugrel and ticagrelor as first choice in this bleeding-risk patient; clopidogrel has a more favorable bleeding profile when GI risk is high.

Anticoagulation

• Start unfractionated heparin or enoxaparin at adjusted dose for ACS unless actively bleeding. If there is any concern about ongoing occult GI bleeding, UFH is preferable because it is rapidly reversible and shorter-acting.
• Avoid glycoprotein IIb/IIIa inhibitors and bivalirudin is not indicated here.

Gastroprotection

• Continue high-dose PPI (e.g., pantoprazole) and confirm H. pylori status; treat if positive.
• Transfuse only if Hb falls below ~7-8 g/dL or if symptomatic, using a restrictive threshold.

Anti-ischemic

• Beta-blocker (metoprolol) if no contraindication; nitrates for symptom control; high-intensity statin (atorvastatin 80 mg) - statins do not increase GI bleeding risk.
• Avoid NSAIDs.

Disposition

• Admit to CCU with serial ECGs and troponins. Early invasive strategy within 24 hours is reasonable given intermediate-high risk, but timing should account for bleeding risk; if bleeding recurs, reassess.

Clinical framing for the patient

• Feeling better after nitroglycerin does not mean the artery is open; it means the heart muscle is temporarily getting more blood. The plaque is still there and can close suddenly.
• Patients with NSTEMI and high-risk features (rising troponin, ST depression, diabetes, age) have a substantially higher risk of death or recurrent MI in the weeks after discharge if managed conservatively compared with an invasive strategy.

Guideline basis

• Current ACC/AHA and ESC NSTE-ACS guidelines recommend an early invasive strategy (coronary angiography with intent to revascularize) for patients with high-risk features, including rising troponin, dynamic ST changes, and diabetes.
• Meta-analyses (e.g., FRISC-II, TACTICS-TIMI 18, and the RITA-3 long-term follow-up) show reduced composite ischemic events with routine invasive management in high-risk NSTE-ACS, though benefit is smaller in lower-risk patients.
• Conservative management is appropriate only for low-risk patients (no recurrent symptoms, normal troponin, no ECG changes, low GRACE score). This patient does not fit that profile.

Balancing bleeding risk

• His recent GI bleed raises the periprocedural bleeding risk but does not eliminate the benefit of angiography. Strategies to mitigate: radial access, UFH rather than potent parenteral antiplatelets, PPI cover, and a shorter DAPT duration if PCI is performed with a bleeding-avoidance strategy (e.g., drug-eluting stent with abbreviated DAPT).
• Shared decision-making should document that the thrombotic benefit was judged to outweigh the bleeding risk, with a plan to reassess if bleeding recurs.